RUTI vaccine proceeds through Phase IIb Clinical Trials
Updated: Jan 23, 2020
The vaccine developed by Spanish biopharmaceutical company Archivel Farma received the permission to conduct the clinical trial from the Drug Controller General of India.
The permission was communicated on the 20th of January and comes after joint coordination efforts on behalf of the All India Institute of Medical Sciences (AIIMS), Archivel Farma and Zydus Cadila in defining the protocol titled "Double-Blind, Randomized, Placebo-controlled Phase IIb Clinical Trial, to Investigate the Efficacy of RUTI Therapeutic vaccination as adjuvant of Tuberculosis chemotherapy".
The clinical trials will take place at the All India Institute of Medical Sciences facilities in New Delhi and at the Department of Microbiology of the Agartala Government Medical College in Tripura.